No Data
No Data
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for amyotrop
Express News | Shares of Biogen and Ionis Pharmaceuticals Are Trading Lower After the Company Discontinued Development of ALS Candidate BIIB105
Ionis to Fly Solo on Angelman Syndrome Drug -- Market Talk
1152 ET - Ionis Pharmaceuticals will advance its ION582 candidate for the genetic disorder Angelman syndrome after partner Biogen elected not to exercise its option to license and lead development of
Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study
Ionis Pharmaceuticals (IONS) said Thursday that topline data from a phase 1/2a study showed that ION582 improved cognition, communication, and motor function in patients with Angelman syndrome. The st
Express News | Biogen Shares Down 1.7%
Sector Update: Health Care Stocks Steady Premarket Thursday
Health care stocks were steady premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. Arvinas (ARVN) shares were up more than